



(51) International Patent Classification:

A61K 47/68 (2017.01) C07K 16/28 (2006.01)
C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2022/029533

(22) International Filing Date:

17 May 2022 (17.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/189,503 17 May 2021 (17.05.2021) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.**
[US/US]; Biohaven Therapeutics Ltd., 215 Church Street,
New Haven, Connecticut 06510 (US).

(72) Inventors: **KAZMIERSKI, Wieslaw**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **PRACITTO, Richard**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS




Fig. 1

(57) Abstract: A composition including a first compound having the structure P-N-L^{PM}-MOI, wherein P-N is a protein agent moiety comprising a lysine residue, L^{PM} is a linker, and MOI is a moiety of interest, and a second compound having the structure LG-OH, wherein LG is a group comprising a target binding moiety that binds to a target agent.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*